Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer
- 7 February 2008
- journal article
- review article
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1785 (2) , 232-265
- https://doi.org/10.1016/j.bbcan.2008.01.001
Abstract
No abstract availableKeywords
This publication has 315 references indexed in Scilit:
- Development of an ovarian cancer symptom indexCancer, 2007
- Alterations in the p53 pathway and prognosis in advanced ovarian cancer: A multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865)European Journal Of Cancer, 2006
- An EGF receptor inhibitor induces RAR-β expression in breast and ovarian cancer cellsBiochemical and Biophysical Research Communications, 2005
- Cytotoxicity of the novel anti-cancer drug rViscumin depends on HER-2 levels in SKOV-3 cellsBiochemical and Biophysical Research Communications, 2004
- Identification of a Natural Soluble Form of the Vascular Endothelial Growth Factor Receptor, FLT-1, and Its Heterodimerization with KDRBiochemical and Biophysical Research Communications, 1996
- The prognostic value of epidermal growth factor receptors, determined by both immunohistochemistry and ligand binding assays, in primary epithelial ovarian cancer: a pilot studyEuropean Journal Of Cancer, 1993
- c-erbB3 Gene Encodes Secreted as Well as Transmembrane Receptor Tyrosine KinaseBiochemical and Biophysical Research Communications, 1993
- Cloning and Expression of cDNA Encoding Human Betacellulin, a New Member of the EGF FamilyBiochemical and Biophysical Research Communications, 1993
- Occurrence of epidermal growth factor receptors in benign and malignant ovarian tumors and normal ovarian tissues: an immunohistochemical studyZeitschrift für Krebsforschung und Klinische Onkologie, 1992
- Epidermal growth factor receptor and transforming growth factor alpha expression in human ovarian carcinomasEuropean Journal Of Cancer, 1992